Ruggell - Liechtenstein, Vienna - Austria 14 March 2017 -
Ruggell, Liechtenstein, 14 March 2017 - Pantec Biosolutions AG and the Medical University Vienna today announced to start a Phase I trial of EPIMMUN Influenza.
The EPIMMUN Influenza skin vaccination program intends to compare the safety and efficacy of epidermal delivery using PANTEC’s needleless and adjuvantfree technology, EPIMMUN, to the conventional intradermal injection of one dose of Sanofi Pasteur/MSD Seasonal Influenza Vaccine INTANZA 15μg.
One Cohort of 10 subjects will be assigned to receive laser-assisted epidermal application of INTANZA and the other Cohort of 10 subjects will be assigned to receive the standard intradermal application of INTANZA. The immunogenicity against Influenza Virus of both Cohorts will be compared 29 days after study vaccination.
This Phase I proof of concept study is being conducted under the supervision of Dr. Christa Firbas from University Clinic for Clinical Pharmacology of the Medical University Vienna and is sponsored by Pantec Biosolutions.
About Pantec Biosolutions AG and P.L.E.A.S.E.® Professional
Pantec Biosolutions is a privately held company located in Liechtenstein, specializing in precise skin microporation technology. Our proprietary P.L.E.A.S.E.® (Precise Laser EpidermAl SystEm) technology has been developed for:
Pantec Biosolutions’ first product P.L.E.A.S.E.® Professional was awarded a red dot design award in 2010. www.pantec-biosolutions.com